Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026, specifically dated February 5, 2026. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the registrant.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific equity transactions.
| Transaction Date | Instrument | Transaction Type | Volume | Price (GBP) | Total Value (Approx.) |
|---|---|---|---|---|---|
| 2026-02-05 | Ordinary Shares (ISIN: GB00BN7SWP63) | Sale | 100,000 | 21.0900 | £2,109,000 |
| 2026-02-05 | Ordinary Shares (ISIN: GB00BN7SWP63) | Sale | 2,000 | 20.8700 | £41,740 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate sales of ordinary shares on the London Stock Exchange (XLON) executed on the same day.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of share disposals by:
- David Redfern (President, Corporate Development): Sold 100,000 shares.
- Neil Falkingham (PCA of Lynn Baxter, President, Europe): Sold 2,000 shares.
Investor Verification Checklist
- Verify the total number of shares held by David Redfern and Neil Falkingham post-transaction to assess remaining insider exposure.
- Confirm if these sales were part of a pre-arranged trading plan (Rule 10b5-1 equivalent) or discretionary decisions.
- Compare the transaction prices (£21.09 and £20.87) against the closing market price of GSK shares on February 5, 2026.
- Review subsequent filings to determine if these transactions were part of a larger divestment trend by senior management.